recombinant human relaxin
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pre-Eclampsia
Conditions
Pre-Eclampsia
Trial Timeline
Oct 1, 2006 → —
NCT ID
NCT00333307About recombinant human relaxin
recombinant human relaxin is a phase 1 stage product being developed by Novartis for Pre-Eclampsia. The current trial status is active. This product is registered under clinical trial identifier NCT00333307. Target conditions include Pre-Eclampsia.
What happened to similar drugs?
0 of 1 similar drugs in Pre-Eclampsia were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00333307 | Phase 1 | Active |
Competing Products
3 competing products in Pre-Eclampsia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + RLX030 | Novartis | Phase 2 | 27 |
| Sildenafil citrate | Pfizer | Phase 2 | 27 |
| Furosemide | Pacific Biosciences | Phase 3 | 30 |